Europe Bioinformatics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Application, and Sector

The Europe bioinformatics market is expected to grow from US$ 3,626.93 million in 2022 to US$ 8,615.56 million by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.

Many private organizations and government bodies of various countries in the region are progressively investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which have developed the quality of bioinformatics services. For instance, in 2016, the European Molecular Biology Laboratory (EMBL), an intergovernmental organization and pioneer in bioinformatics research, received funds from various organizations such as the British Heart Foundation, Biotechnology and Biological Sciences Research Council, European Molecular Biology Organization, Cancer Research UK, the European Research Council, the European Commission, the Foundation of the National Institutes of Health, Bill & Melinda Gates Foundation, the Human Frontier Science Program, International Policy Governance Organization, the Medical Research Council, the National Institutes of Health, National Science Foundation, Parkinson's UK, Research Councils UK, and Wellcome, for R&D in the field of bioinformatics. Also, in 2021, LifeArc (London) announced US$ 6.91 million in funding to support the Gen OMICC COVID-19 study, which will also support the bioinformatics analysis of patients, costs of patient enrolment, sample acquisition, and sample processing. Many countries are investing in their national population sequencing programs to identify the link between genetics and diseases. Government organizations are sequencing the genomes of millions of citizens to advance research and help develop better techniques to diagnose and treat cancer, rare diseases, and other conditions. Thus, the funding and investment in bioinformatics are boosting the market growth across the region.

Market Overview

The European bioinformatics market is segmented into the UK, Germany, France, Italy, Spain, and Rest of Europe. Germany dominated the market in 2022. The growing importance of bioinformatics in drug development and rising initiatives by key players are aiding the market growth in Germany. For instance, in January 2022, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launched a CRO named ProtaGene. It provides protein and gene analytic services for biological therapeutics and cell & gene therapy platforms, from discovery to commercialization. Protagen Protein Services, a global analytic CRO and specialist in protein science; BioAnalytix, US-based advanced analytics and data analysis firm; and GeneWerk, a company having unique capabilities in vector safety, integration site analysis, and bioinformatics, are a few companies operating in the market. In September 2019, Brooks Life Sciences Company’s GENEWIZ, a global bioinformatics services provider, opened its European headquarters for its genomics business in Leipzig, Germany. This centralized location helped accelerate the innovation and development of genomics research and applications in pharmaceutical, biotechnology, agriculture, environmental, clean energy, academic, and other industries in Europe. In February 2022, Nostos Genomics, a German startup, received a US$ 5.28 million investment for using Artificial Intelligence (AI) to diagnose rare genetic diseases. With the funding, Nostos can grow its development team, start a research series, and promote its genetic disease diagnosis technology to new markets in Europe. Thus, Germany continues to dominate the Europe bioinformatics market owing to rapid advancements in bioinformatics technologies and increased funding for genomic research using bioinformatics tools.

Europe Bioinformatics Market Segmentation

The Europe bioinformatics market is segmented on the basis of product, application, sector, and country.

• Based on product, the Europe bioinformatics market is segmented into knowledge management tools, bioinformatics platforms, and bio informative services. The bioinformatics platforms segment held the largest market share in 2022.
• Based on application, the Europe bioinformatics market is segmented into genomics, chemo informatics and drug design, proteomics, transcriptomics, metabolomics, and others. The genomics segment held the largest market share in 2022.
• Based on sector, the Europe bioinformatics market is segmented into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, forensic biotechnology, and others. The medical biotechnology segment held the largest market share in 2022.
• Based on country, the Europe bioinformatics market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Further, Germany dominated the market in 2022. Agilent Technologies, Inc.; Biomax Informatics AG; Bruker Corporation; Dassault Systèmes; Eurofins Scientific; Genebio; Illumina, Inc.; PerkinElmer Inc.; QIAGEN; and Thermo Fisher Scientific Inc. are the leading companies operating in the Europe bioinformatics market.